AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04453423
Drug: Anlotinib + Pemetrexed+Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anlotinib: 12mg, QD, PO, d1-14, 21 days per cycle~Carboplatin: AUC 5 on day 1 of 21 days per cycle~Pemetrexed: 500mg/m2 iv on day 1 of 21 days per cycle
Trial: NCT04453423
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)
Trial: NCT04453423
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)
Trial: NCT01142063
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet, a 240 mg single oral dose
Trial: NCT04223752
Drug: Ceftolozane/Tazobactam
RxNorm normalized name: CEFTOLOZANE/TAZOBACTAM
DrugBank: Tazobactam (DB01606)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants 12 to \<18 years of age: IV ceftolozane 2 g with tazobactam 1 g infused over a 60-minute period.~Participants \<12 years of age: IV ceftolozane 40 mg/kg with tazobactam 20 mg/kg infused over a 60-minute period (not to exceed a dose of ceftolozane 2g and tazobactam 1 g).
Trial: NCT03132636
Drug: cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regimen as per protocol
Trial: NCT00112528
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00112528
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00895245
Drug: fosaprepitant dimeglumine
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00895245
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00895245
Drug: palonosetron hydrochloride
RxNorm normalized name: Palonosetron Hydrochloride
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00895245
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV and orally
Trial: NCT01857999
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02222350
Drug: 10mg DS-8500a tablet
RxNorm normalized name: prednisone 10 MG [Sterapred DS]
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03659916
Drug: A4250 (odevixibat)
RxNorm normalized name: Odevixibat
DrugBank: Odevixibat (DB16261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A4250 is a small molecule and selective inhibitor of IBAT
Trial: NCT02424968
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02424968
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03516071
Drug: Brivanib 800 mg, QD
DrugBank: Brivanib (DB11958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib Alaninate 800 mg QD, PO
Trial: NCT03516071
Drug: Brivanib 400 mg, BID
DrugBank: Brivanib (DB11958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib Alaninate 400 mg BID, PO
Trial: NCT03333824
Drug: CYP2C19 (omeprazole)
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
Trial: NCT03333824
Drug: CYP3A (midazolam)
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
Trial: NCT03333824
Drug: Kytril (granisetron)
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients should be administered Kytril (granisetron) 1 mg orally, under fasted conditions (-2 to 2 hours away from meals), 30 minutes prior to administration of the AZD1775 capsules with a small amount of water.
Trial: NCT03933618
Drug: Anastrozole 1mg
RxNorm normalized name: ANASTROZOLE 1MG TAB
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03933618
Drug: Clomiphene Citrate 25mg
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02895113
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients suffering from type 2 diabetes will be randomized to receive 100 mg/day or placebo for one year
Trial: NCT03990194
Drug: Leuprolide Acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Leptoprol implant every 3 months
Trial: NCT02395133
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.
Trial: NCT01249638
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab: 7.5 mg/kg day 1 q day 21
Trial: NCT01249638
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan: 200 mg/m2 day 1 , q day 21
Trial: NCT01249638
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab: 7.5 mg/kg day 1, q day 21
Trial: NCT04422392
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (IV, Q3W)
Trial: NCT04422392
Drug: Pemetrexed or Nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel (Squamous NSCLC) (IV, Q3W)
Trial: NCT04422392
Drug: PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (IV, Q3W)
Trial: NCT02671266
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.
Trial: NCT01443221
Drug: mitiglinide and metformin
RxNorm normalized name: metformin and ertugliflozin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Free combination of Mitiglinide 10mg and Metformin 500mg
Trial: NCT01443221
Drug: mitiglinide and metformin
RxNorm normalized name: metformin and ertugliflozin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
Trial: NCT02165332
Drug: Part 2: Treatment C, moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose moxifloxacin and RO7033877 placebo
Trial: NCT02165332
Drug: Part 2: Treatment D, RO7033877 and moxifloxacin placebo
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose moxifloxacin placebo and RO7033877 placebo
Trial: NCT00110370
Drug: Glargine Basal-Bolus Therapy
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01974700
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days
Trial: NCT01738880
Drug: SVV
RxNorm normalized name: SVV-001
DrugBank: SVV-001 (DB06129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the surgery, patients in group S receive additional fluids (400 ml of normal saline or 200 ml of colloid) when SVV is less than 13.
Trial: NCT03732625
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs that constituted the triple therapy established before the inclusion of the patient in the study.
Trial: NCT00946335
Drug: veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00946335
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01018225
Drug: darifenacin
RxNorm normalized name: Darifenacin
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7.5 or 15 mg darifenacin, once a day for 6 weeks
Trial: NCT00583622
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg by vein daily over 90 minutes for 2 Days
Trial: NCT00583622
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 333 mg/m\^2 by vein over 2 hours for 3 Days
Trial: NCT00583622
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg/m\^2 by vein over 2 hours for 1 Day
Trial: NCT00583622
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,800 mg/m2 by vein over 3 hours for 4 Days
Trial: NCT00583622
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 by vein over 15 minutes for 3 Days
Trial: NCT00778284
Drug: Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000161
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000161
Drug: Beta-Carotene
RxNorm normalized name: Beta-carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000161
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000161
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02484170
Drug: Mannitol cream
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months
Trial: NCT01075646
Drug: ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laparotomy of colorectal surgery: 10 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 5ml/h.~Laparoscopy of colorectal surgery: 5 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 2 ml/h.~Hepatic surgery: 10 ml de ropivacaine 0,45% + infusion with elastomeric pump with ropivacaine 0,23 at a 5ml/h.
Trial: NCT01075646
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laparotomy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h.~Laparoscopy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 2 ml/h.~Hepatic surgery: 10 ml de saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h
Trial: NCT02228239
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine 84 milligram (mg) \[3\*1 of spray in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.
Trial: NCT02228239
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.
Trial: NCT02228239
Drug: Placebo (Matched to Esketamine)
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo \[3\*1 in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.
Trial: NCT00402194
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, 100mg, once per day for 3 months
Trial: NCT02260076
Drug: PEG 400
RxNorm normalized name: PEG 400
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03315130
Drug: zilucoplan (RA101495)
RxNorm normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous (SC) injection
Trial: NCT03133299
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D for two months
Trial: NCT01844180
Drug: ONO-2952
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01844180
Drug: ONO-2952 Matching Placebo
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02256982
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02256982
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03648671
Drug: safinamide metansolfonato (12 weeks)
DrugBank: Safinamide (DB06654)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: safinamide metansolfonato
Trial: NCT03648671
Drug: rasagilina mesilato (12 weeks)
RxNorm normalized name: Rasagilina
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rasagilina mesilato
Trial: NCT02418689
Drug: NOV120101 (Poziotinib)
RxNorm normalized name: Poziotinib
DrugBank: Poziotinib (DB12114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development
Trial: NCT04432714
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
Trial: NCT04432714
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2，IV, d0
Trial: NCT04432714
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 50 mg/m2/day CI24h d1-d4
Trial: NCT04432714
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine 0.4mg/m2/day CI24h d1-d4
Trial: NCT04432714
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 60 mg/m2/bid oral or IV d1-d5
Trial: NCT02504801
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To test the hypothesis that nebulizer Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two arms among primary lung cancer patients with COPD required single lobectomy from 3 days before operation to 7 days after operation.
Trial: NCT02706483
Drug: Plecanatide
RxNorm normalized name: Plecanatide
DrugBank: Plecanatide (DB13170)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001930
Drug: Amantadine
RxNorm normalized name: Amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02684032
Drug: Gedatolisib
RxNorm normalized name: Gedatolisib
DrugBank: Gedatolisib (DB11896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
Trial: NCT02684032
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
Trial: NCT02684032
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole at 2.5 mg daily
Trial: NCT02684032
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
Trial: NCT00053300
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity
Trial: NCT02350686
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
Trial: NCT01345981
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage 20 mg and 40 mg
Trial: NCT01813214
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01813214
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00831714
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made
Trial: NCT03790670
Drug: sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
Trial: NCT00687297
Drug: vandetanib induction
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg daily by mouth
Trial: NCT00687297
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
Trial: NCT00687297
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
Trial: NCT00687297
Drug: Vandetanib maintenance
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg daily by mouth
Trial: NCT00370318
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03829618
Drug: Topical lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1% lidocaine topically applied in 4 mL aliquots
Trial: NCT03829618
Drug: Nebuliser solution
RxNorm normalized name: Pentamidine isetionate 300 mg powder for nebuliser solution vial
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% lidocaine dose at 2 mg/kg (max 160 mg) applied via jet nebulizer
Trial: NCT00688415
Drug: VTX-2337
RxNorm normalized name: VTX-801
DrugBank: VTX-801 (DB17646)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.
Trial: NCT01876784
Drug: Vandetanib (SAR390530)
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT00642096
Drug: Metoprolol Succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no